Gross tumor volume delineation in primary prostate cancer on 18F-PSMA-1007 PET/MRI and 68Ga-PSMA-11 PET/MRI

[1] Siegel RL(2020)Cancer statistics, 2020 CA Cancer J Clin 70 7-30

[2] Miller KD(2019)Practice patterns of primary EBRT with and without ADT in prostate cancer treatment Prostate Cancer Prostatic Dis 22 117-124

[3] Jemal A(2012)High-dose conformal radiotherapy reduces prostate cancer-specific mortality: results of a meta-analysis Int J Radiat Oncol Biol Phys 83 e619-e625

[4] Schmidt B(2018)An update of pitfalls in prostate mpMRI: a practical approach through the lens of PI-RADS v. 2 guidelines Insights Imaging 9 87-101

[5] Eapen RS(2018)Clinical perspectives of PSMA PET/MRI for prostate cancer Clinics (Sao Paulo) 73 e586s-235

[6] Cowan JE(2016)Current use of PSMA-PET in prostate cancer management Nat Rev Urol 13 226-97

[7] Broering JM(2016)MRI versus (6)(8)Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer Eur J Nucl Med Mol Imaging 43 889-237

[8] Greene KL(2017)Comparison of 68Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology Theranostics 7 228-1216

[9] Carroll PR(2020)Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study Lancet 395 1208-7

[10] Viani GA(2018)Advantage of (18)F-PSMA-1007 over (68)Ga-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretion Eur J Nucl Med Mol Imaging 45 1076-213

[1] Siegel RL(2020)Cancer statistics, 2020 CA Cancer J Clin 70 7-30

[2] Miller KD(2019)Practice patterns of primary EBRT with and without ADT in prostate cancer treatment Prostate Cancer Prostatic Dis 22 117-124

[3] Jemal A(2012)High-dose conformal radiotherapy reduces prostate cancer-specific mortality: results of a meta-analysis Int J Radiat Oncol Biol Phys 83 e619-e625

[4] Schmidt B(2018)An update of pitfalls in prostate mpMRI: a practical approach through the lens of PI-RADS v. 2 guidelines Insights Imaging 9 87-101

[5] Eapen RS(2018)Clinical perspectives of PSMA PET/MRI for prostate cancer Clinics (Sao Paulo) 73 e586s-235

[6] Cowan JE(2016)Current use of PSMA-PET in prostate cancer management Nat Rev Urol 13 226-97

[7] Broering JM(2016)MRI versus (6)(8)Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer Eur J Nucl Med Mol Imaging 43 889-237

[8] Greene KL(2017)Comparison of 68Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology Theranostics 7 228-1216

[9] Carroll PR(2020)Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study Lancet 395 1208-7

[10] Viani GA(2018)Advantage of (18)F-PSMA-1007 over (68)Ga-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretion Eur J Nucl Med Mol Imaging 45 1076-213